Invention Grant
US09296808B2 Methods for treating scleroderma by administering a soluble CTLA4 molecule
有权
通过施用可溶性CTLA4分子治疗硬皮病的方法
- Patent Title: Methods for treating scleroderma by administering a soluble CTLA4 molecule
- Patent Title (中): 通过施用可溶性CTLA4分子治疗硬皮病的方法
-
Application No.: US14193687Application Date: 2014-02-28
-
Publication No.: US09296808B2Publication Date: 2016-03-29
- Inventor: Robert Cohen , Suzette Belder-Carr , David Hagerty , Robert James Peach , Jean-Claude Becker
- Applicant: Bristol-Myers Squibb Company
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Nickki Parlet
- Main IPC: C07K14/705
- IPC: C07K14/705 ; A61K39/395 ; A61K38/00 ; A61K39/00
Abstract:
The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Public/Granted literature
- US20140286948A1 METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE Public/Granted day:2014-09-25
Information query
